Gharaibeh Shatha, Shurman Abdallah, Gharaibeh Abeer, Torcuator Roy
Center for Cognition and Neuroethics, University of Michigan-Flint, Flint, USA.
Clinical Research, Insight Research Institute, Flint, USA.
Cureus. 2024 Aug 14;16(8):e66846. doi: 10.7759/cureus.66846. eCollection 2024 Aug.
Fibrinolytic and coagulative hyperactivity is proven to have a role in liquefaction and progression of chronic subdural hematoma (CSDH). Tranexamic acid was one of the pharmaceutical options that was explored, as it inhibits the hyper-fibrinolytic activity and reduces the vascular permeability in CSDH, leading to a gradual resolution of the hematoma. In this case study, we present a case of using tranexamic acid for CSDH treatment in an 86-year-old patient with co-morbidities. The complete resolution of the hematoma following using tranexamic acid in this case with no history of recurrence in two years follow-up supports its efficacy in CSDH treatment and may be considered as one of the strategies that help prevent surgeries.
纤维蛋白溶解和凝血功能亢进被证明在慢性硬膜下血肿（CSDH）的液化和进展中起作用。氨甲环酸是探索的药物选择之一，因为它抑制CSDH中的高纤维蛋白溶解活性并降低血管通透性，从而导致血肿逐渐消退。在本病例研究中，我们展示了一例在一名患有多种合并症的86岁患者中使用氨甲环酸治疗CSDH的病例。该病例使用氨甲环酸后血肿完全消退，在两年随访中无复发史，这支持了其在CSDH治疗中的疗效，并且可被视为有助于避免手术的策略之一。
